{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-190202","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2025-08-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.603135+00:00","generated_at":"2026-05-17T09:28:40.960133+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ARS Pharma receives Paragraph IV notice from Lupin for generic neffy; intends to sue","bullets":["Lupin filed ANDA for generic version of neffy (epinephrine nasal spray) before expiration of 8 Orange Book-listed patents.","Notice alleges patents are invalid, unenforceable, or not infringed; ARS plans to file patent infringement suit within 45 days.","Filing suit within 45 days triggers automatic 30-month FDA approval stay; company vows to vigorously defend IP.","As of filing, no other ANDA filers known; neffy is ARS's sole marketed product."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-190202","json":"https://secwatch.observer/filing/0001193125-25-190202.json","markdown":"https://secwatch.observer/filing/0001193125-25-190202.md","text":"https://secwatch.observer/filing/0001193125-25-190202.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000119312525190202/0001193125-25-190202-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000119312525190202/d88536d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T09:28:40.960133+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}